Blockade of the programmed cell death protein/ligand 1 (PD-1/PD-L1) pathway with monoclonal antibodies (mAb) is now commonly used for cancer immunotherapy and has therapeutic potential in chronic viral infections including HIV-1. PD-1/PD-L1 blockade could augment HIV-1-specific immune responses and reverse HIV-1 latency, but the latter effect has not been clearly shown. We tested the ability of the human anti-PD-L1 mAb BMS-936559 and the human anti-PD-1 mAb nivolumab to increase HIV-1 virion production ex vivo from different peripheral blood mononuclear cell populations obtained from donors on suppressive antiretroviral therapy (ART). Fresh peripheral blood mononuclear cells (PBMC), CD8-depleted PBMC, total CD4 + T cells, and resting CD4 + T cells were purified from whole blood of HIV-1-infected donors and cultured in varying concentrations of BMS-936559 (20, 5, or 1.25μg/mL) or nivolumab (5 or 1.25μg/mL), with or without anti-CD3/CD28 stimulatory antibodies. Culture supernatants were assayed for virion HIV-1 RNA by qRT-PCR. Ex vivo exposure to BMS-936559 or nivolumab, with or without anti-CD3/CD28 stimulation, did not consistently increase HIV-1 virion production from blood mononuclear cell populations. Modest (2-fold) increases in virus production were observed in a subset of donors and in some cell types but were not reproducible in longitudinal samples. Cell surface expression of PD-1 and PD-L1 were not associated with changes in virus production. Ex vivo blockade of the PD-1 axis alone has limited effects on HIV-1 latency.
Introduction
Antiretroviral therapy (ART) does not cure HIV-1 infection because of a persistent reservoir of cells carrying intact proviruses that are capable of infectious virus production, leading to virus replication, spread and rebound viremia if ART is stopped [1] [2] [3] [4] [5] [6] [7] [8] . The "shock and kill" PLOS ONE | https://doi.org/10.1371/journal.pone.0211112 January 25, 2019 1 / 15 a1111111111 a1111111111 a1111111111 a1111111111 a1111111111
strategy for an HIV-1 cure aims to deplete the HIV-1 reservoir by reversing latency and promoting the death of infected cells, either by viral cytopathic effect or by immune-mediated killing [9] . Immune checkpoint blockade is a strategy that has been investigated for its potential to enhance HIV-1-specific immunity [10] , and promote proviral expression (i.e., provide a "kick") by activation of infected CD4 + T cells. Generally, immune checkpoints regulate the immune system to promote self-tolerance and limit inflammation to minimize collateral tissue damage [10, 11] . In chronic HIV-1 infection, immune checkpoint expression is increased both in individuals with uncontrolled viremia and in those on ART with suppression of viremia [12, 13] , and is associated with more rapid HIV-1 disease progression [14] and shorter time to viral rebound following ART cessation [15] . This important role of immune checkpoint expression is further supported by ex vivo studies using human cells and in vivo studies in both animal models and humans demonstrating that HIV-1-specific immune function is augmented by blockade of immune checkpoints [10, [16] [17] [18] [19] . The FDA has approved monoclonal antibodies (mAb) for the treatment of cancer that block the immune checkpoints cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and the programmed cell death protein 1 (PD-1), or one of its two natural ligands, PD-L1. Ipilimumab, an anti-CTLA-4 mAb, was FDA approved in 2011 for treatment of metastatic melanoma after it was shown to improve overall survival [20] . However, the associated toxicities with ipilimumab are likely too severe to be used in HIV-1-infected individuals on ART who are otherwise healthy [10, 21] .
Multiple therapies targeting the PD-1/PD-L1 axis have been approved by the FDA. Nivolumab, an anti-PD-1 mAb, is approved for treatment of head and neck squamous cell cancer (HNSCC), Hodgkin lymphoma, advanced melanoma, non-small cell lung cancer (NSCLC), renal cell cancer, and urothelial cancer. Other antibodies targeting the PD-1/PD-L1 axis include pembrolizumab (anti-PD-1), durvalumab (anti-PD-L1), avelumab (anti-PD-L1), and atezolizumab (anti-PD-L1). PD-1 blockade has led to improved survival and lower rates of high-grade toxicities in advanced melanoma compared to CTLA-4 blockade [22, 23] . Limited case reports suggest that blockade of the PD-1/PD-L1 axis may also promote anti-HIV immune responses in HIV-1 infected patients [18, [24] [25] [26] . PD-L1 blockade with BMS-936559 was also shown to be generally well-tolerated in HIV-1-infected participants and resulted in increased HIV-1 gag-specific polyfunctional CD8 + T cell responses [16] . These preliminary data suggest that blockade of the PD-1 axis has a potential role in immune control of HIV-1.
To address the possibility that immune checkpoint blockade can reverse HIV-1 latency, the effects of anti-PD-L1 (BMS-936559) or anti-PD-1 (nivolumab) mAb on virus production were assessed ex vivo with different cell populations from HIV-1-infected individuals on long-term suppressive ART. Cultured cells were incubated with increasing concentrations of BMS-936559 or nivolumab, with or without anti-CD3/CD28 stimulation, followed by measurement of virion release into the cell culture supernatants. Cell viability and PD-1/PD-L1 expression were also measured and examined for associations with HIV-1 production.
Results

Donor characteristics
Experiments were performed with blood samples drawn from 16 chronically HIV-1-infected volunteers on suppressive ART with plasma HIV-1 RNA <50 copies (cp)/mL (Table 1) . A subset of donors had samples drawn at multiple, longitudinal time points to assess the reproducibility of observed ex vivo responses. 
Blockade with anti-PD-L1 mAb (BMS-936559)
The effects of BMS-936559, a fully human IgG 4 anti-PD-L1 monoclonal antibody [27] , on HIV-1 production were determined for PBMC, total CD4 + T cells, and/or resting CD4 + T cells, all derived from fresh whole blood. Resting CD4 + T cells were CD69 neg CD25 neg H-LA-DR neg . Cells were incubated with either (1) BMS-936559 at concentrations that reflect therapeutic plasma concentrations (1.25, 5, and 20μg/mL) [27] , (2) an isotype control antibody, (3) media alone (no-Ab control), or (4) anti-CD3/CD28 antibody-coated beads (Dynabeads, Invitrogen). Following seven days of culture, virion production was measured as HIV-1 RNA in cell-free supernatant using qRT-PCR [28] . Cell viability was measured using CellTiter-Fluor (Promega).
Experiments with BMS-936559 were performed with cells from 12 donors ( For statistical analyses, virion production below the assay limit of detection (30 cp/mL culture supernatant) was considered non-detectable and set at 0 cp/mL. Cell viability was normalized to the no-Ab control for each cell population within each donor. Donor D1 had high levels of spontaneous virion production in the no-Ab and isotype controls (up to 15,290 cp/mL) and was excluded from analyses. The raw data for virion production is tabulated in S1 Table. Median HIV-1 RNA levels in supernatants from medium control cells for the other 11 donors was 50 cp/mL. Anti-CD3/CD28 treatment led to statistically significant increases in virion production from each cell population compared to isotype controls (PBMC: median 1746 cp/mL, p<0.01; total CD4 + T cells: median 18,773 cp/mL, p<0.01; resting CD4 + T cells:
median 886 cp/mL, p<0.01; by Wilcoxon matched-pairs signed rank test) ( Fig 1A, S1 Fig) . Anti-CD3/CD28 stimulation also increased cell viability for total CD4 + and resting CD4 + T cell types (total CD4 + T cells: median 3.9-fold increase, p = 0.02; resting CD4 + T cells: median 3.3-fold increase, p = 0.03; by Wilcoxon matched-pairs signed rank test) ( Fig 1B) . No significant increases in cell viability of PBMC were observed following anti-CD3/CD28 stimulation. Across all donors, none of the concentrations of BMS-936559 resulted in statistically significant differences in virion production or cell viability compared to the isotype control for each cell population (Fig 1) . Despite the lack of a statistically significant overall virologic response to BMS-936559, we investigated whether cell types or certain BMS-936559 concentrations were associated with increased virus production (i.e., virus activation), defined as 2-fold greater HIV-1 RNA (cp/ mL) in supernatants from cells treated with BMS-936559 compared to isotype control. If the isotype control led to virion production below the assay limit of detection (30 cp/mL of culture supernatant), then a response was defined as twice the limit of detection (>60 cp/mL). So defined, virus activation responses were observed for at least one concentration of BMS-936559 in at least one cell population from 7 of 11 donors. More specifically, virus activation responses were observed in PBMC from 4 of 11 donors (median 706 cp/mL for conditions producing virus activation), in total CD4 + T cells from 4 of 10 donors (median 81 cp/mL), and Although virologic responses to BMS-936559 were not significant or reproducible, we hypothesized that blockade of PD-L1 alone may be insufficient to activate virus production and would require stimulation once the inhibitory effect of PD-L1 was removed. The PD-1 axis is known to suppress T cell receptor (TCR) signaling, so PD-1 axis blockade may increase HIV-1 latency reversal in T cells that are stimulated via the TCR [30, 31] . To investigate this possibility, additional experiments were performed using cells from three donors who showed >2-fold virus activation responses to BMS-936559 (Donors W7, C5, K5). For each donor, the same cell populations that responded to BMS-936559 previously without additional stimulation were studied. Cells were stimulated using anti-CD3/CD28 antibody-coated beads (1 bead per cell) and cultured alone, with BMS-936559 at varying concentrations (1.25, 5, and 20 μg/ mL), or with an isotype control. Virion production and cell viability were measured following seven days of culture, as described above, and were normalized relative to stimulation with anti-CD3/CD28 alone. None of the concentrations of BMS-936559 in anti-CD3/CD28-stimulated cells resulted in statistically significant increases in virion production or cell viability compared to isotype control (S3 Table) .
Blockade with anti-PD-1 (nivolumab)
The ability of PD-1 blockade using nivolumab, a fully human IgG 4 anti-PD-1 mAb [23, [32] [33] [34] [35] [36] [37] [38] [39] [40] , to activate virus production was also evaluated ex vivo. The experimental methods were similar to above, except with modification of the cell types tested. Of the different cell populations assessed for virus activation responses to BMS-936559, PBMC and total CD4 + T cells had the greatest proportion of responses across donors. The greater response rates in PBMC may be caused by PD-L1 expression on antigen-presenting cells [41] and the greater response rates in total CD4 + T cells may be caused by the presence of activated CD4 + T cells [42, 43] . Since blockade of the PD-1 axis can improve HIV-1-specific CD8 + T cell function [10] , CD8-depleted PBMC were also evaluated for virus activation in response to nivolumab. The limited cell yields from large volume phlebotomies (180mL) did not permit assessment of all four cell populations, so resting CD4 + T cells were excluded from experiments with nivolumab because they had the fewest virus activation responses to BMS-936559. Virus activation by nivolumab was assessed by culturing cells with either media alone, with nivolumab at varying concentrations that reflect therapeutic plasma concentrations (5 or 20 μg/mL) [32, 40] , or with isotype control, with or without anti-CD3/CD28 antibody-coated beads. Following seven days of treatment, virion production and cell viability were measured, as described above. The raw data for virion production is included in S3 Table. Ex vivo responses to nivolumab were evaluated in ten donors. Of these donors, the median age was 54.5 years (range [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] (Fig 2A) or cell viability (Fig 2B) across donors compared to isotype control for each of the cell populations tested (p>0.05 by Wilcoxon matched-pairs signed rank test). In additional analyses, virus activation responses were defined as a 2-fold or greater increase in virion production from cells treated with nivolumab relative to cells treated with isotype control. As above, if the isotype control had virion production below the assay limit of detection (30 cp/mL) then a response was defined as twice the limit of detection (>60 cp/mL). For cells treated with nivolumab alone, 2-fold virus activation responses were observed for at least one concentration of nivolumab in at least one cell population from 3 of 9 donors. Responses were observed in PBMC from 2 of 9 donors (median 234 cp/mL in conditions with virologic responses), in CD8-depleted PBMC from 3 of 7 donors (median 248 cp/mL), and in total CD4 + T cells from 2 of 9 donors (median 185 cp/mL). When virologic responses were defined using stricter criteria of 3-fold increased virion production compared to isotype control and >90 cp/mL, virus activation was observed in PBMC from 1 of 9 donors (332 cp/mL), in CD8-depleted PBMC from 3 of 7 donors (median 299 cp/mL), and in total CD4 + T cells For analysis of experiments in which cells were treated with a combination of anti-CD3/ CD28 and nivolumab, the virion production and cell viability levels were normalized relative to the anti-CD3/CD28 only treatment condition. No significant differences in virion production or viability were found in response to nivolumab as compared to isotype control in the anti-CD3/CD28-stimulated cells (p>0.05 by Wilcoxon matched-pairs signed rank test) ( Fig  2C and Fig 2D) .
Immunophenotyping
The immunophenotype of PBMC was characterized using flow cytometry to measure the frequency of PD-1 and PD-L1 surface expression on CD3 (Fig 2A) . Median-fold difference in cell viability across all donors in response to nivolumab or anti-CD3/CD28 stimulation compared to isotype control (Fig 2B) . Median virion production in response to nivolumab in cells stimulated with anti-CD3/CD28 (Fig 2C) . Median cell viability in response to nivolumab in cells stimulated with anti-CD3/CD28 (Fig 2D) . NAC = no-Ab control; IC = isotype control; 3/28 = anti-CD3/CD28; nivo = nivolumab. Error bars = IQR. [53, 54] . Observed responses were associated with CD4 + T cell proliferation [53] , suggesting that PD-1 blockade promoted T cell activation that led to latency reversal. By contrast, other in vivo macaque studies showed no change in viremia when disrupting the PD-1 axis [55, 56] . Preliminary ex vivo human studies have reported that PD-1 blockade can increase virion production in CD4 + T cells from HIV-1-infected viremic donors [57] and in CD4 + T cells with allogeneic cell or cytokine stimulation (IL-7, IL-15) from donors on suppressive ART [58] . A number of case studies of HIV-1-infected individuals with NSCLC or malignant melanoma who were treated with nivolumab or ipilimumab (anti-CTLA4) reported changes in HIV-1 RNA or DNA [17] [18] [19] 59 ]. By contrast, other studies investigating immune checkpoint blockade for the treatment of cancer in HIV-1-infected individuals have not observed changes in plasma HIV-1 RNA and only inconsistent changes in HIV-1 DNA [17] [18] [19] 24, 26, 59] . No changes in residual viremia or cell-associated HIV-1 RNA were observed in HIV-1-infected participants on effective ART without concomitant malignancy in a phase I, randomized, placebo-controlled, single-dose study of BMS-936559 [16] . Results from this clinical trial did not reveal any changes in residual viremia or cell-associated HIV-1 DNA or RNA in 6 of 6 patients treated with 0.3 mg/kg BMS-936559, although there was evidence of improved HIV-1-specific CD8 + T cell function in 2 of 6 participants [16] . The dose in this study was lower than the lowest evaluated doses in phase I clinical studies for cancer [27] and may have been too low to increase virus production.
In the current ex vivo study, BMS-936559 and nivolumab were evaluated at concentrations that reflect therapeutic plasma concentrations and are associated with PD-L1 and PD-1 receptor occupancy of �70%, respectively [27, 32, 40, 60] . We conducted analyses in which virus activation was defined as 2-fold increases in HIV-1 RNA compared to cells treated with isotype control. So defined, virus activation responses in at least one cell type were observed in 7 of 11 donors incubated with BMS-936559 and in 3 of 9 donors with cells treated with nivolumab. However, responses were inconsistent, occurring in varying cell types and at different antibody concentrations. Responses also did not correlate with HIV DNA levels. Baseline PD-1 and PD-L1 expression correlated with virus production, although these results should be re-evaluated in future studies given the small sample size of this study.
Recent studies have shown that the PD-1 axis suppresses CD28 signaling [30] and that effective PD-1 targeted therapy for restoration of CD8 + T cell function requires CD28 co-stimulation [31] . Yet, in our study ex vivo virologic responses to PD-1/L1 blockade were not increased by TCR/CD28 stimulation. It is possible that the stimulation used in this study via anti-CD3/28 coated beads was too potent to observe an augmented response with PD-1/L1 blockade as compared to prior studies, that used allogeneic cell or cytokine stimulation (IL-7, IL-15) [57, 58] . The absence of a consistent effect of PD-1 axis blockade on virus production among the donors studied is likely multifactorial. First, although PD-1 expression is enriched in HIV-1 infected cells, many HIV-1 infected cells do not express PD-1 and would therefore not be expected to respond to PD-1 axis blockade [13, 44] . Second, HIV-1 infected cells that express PD-1 may be resistant to PD-1 axis blockade from severe exhaustion [61] and upregulation of additional immune checkpoints [13, 61] . Co-expression of multiple immune checkpoint molecules is associated with higher frequencies of HIV-infected cells compared to expression of single immune checkpoints [13] , consequently, inhibition of multiple immune checkpoints may be required for more effective HIV-1 latency reversal. Combination blockade of multiple inhibitory receptors has been shown to improve immune responses, although the associated toxicities will limit this approach [23, 62, 63] . Third, it is possible that testing more cells or using more sensitive assays of proviral activation, such as measuring HIV-1 RNA transcripts, could have revealed more subtle effects of immune checkpoint blockade than by measuring virion production. Fourth, the infrequent and variable responses that were not longitudinally reproduced in this study suggests that responses are stochastic, possibly from spontaneous viral activation. It is possible that concomitant stimulation may be required to observe the effects of PD-1 blockade, as observed in previous studies [57, 58] . Finally, in vivo studies, including mouse models, may allow for more rigorous testing of immune checkpoint blockade. Further human clinical trials will be the best determinant of whether immune checkpoint blockade is safe and can meaningfully impact the HIV-1 reservoir, and whether these therapies are safe for people living with HIV-1.
Methods
Quantification of residual plasma viremia by single-copy assay
Plasma was harvested by centrifugation of whole blood at 400 x g for 10 min, followed by additional centrifugation of plasma at 1350 x g for 15 min. Cell-free plasma was stored at -80˚C. HIV-1 RNA was quantified using a two-step qRT-PCR assay that targets the integrase region of pol [29] . The assay limit of detection is 1 copy of RNA per qPCR reaction.
Isolation of PBMC, CD8-depleted PBMC, total CD4 + T cells, and resting CD4 + T cells
Large-volume phlebotomies (180 mL) were performed on patients who were on suppressive ART for �16 months. PBMC were isolated by Ficoll-Paque density gradient centrifugation. CD8 + T cells were removed from PBMC by positive selection using BD iMag anti-human CD8
Particles (BD). Total CD4 + T cells were isolated from PBMC by negative selection using the 
Quantification of HIV DNA by qPCR
Cells were stored in 1x10 6 aliquots at -80˚C. HIV DNA was quantified as previously described [65] .
Assays of cellular viability
Day 7 cells were assessed for viability using CellTiter Fluor (Promega). Fluorescence was read at excitation/emission 390/505nm. 
Flow cytometric analyses
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